Can Jardiance or Farxiga (SGLT2 Inhibitors) Slow Down Diabetic Retinopathy?
SGLT2 Diabetes Pills and Your Retina at a Glance
Some eye changes cannot wait for your next visit. Call your eye doctor the same day if any of these start.
- Sudden vision loss, or vision that turns blurry all at once
- A gray curtain over part of your sight, or a shadow in your side vision
- A sudden shower of new floaters, which look like specks, lines, or cobwebs
- Flashing lights that are new for you
- Severe eye pain, especially with a headache, an upset stomach, or rings around lights
Sudden vision loss, or a sudden change in your vision, needs to be looked at right away1. Many new floaters at once, a shadow in your side vision, or a gray curtain over part of your sight are the signs of a torn or loose retina, and an eye doctor needs to check for it that day2. Severe eye pain with sudden blurring, a headache, an upset stomach, or rings around lights is a true eye emergency3. Advanced diabetic retinopathy is one route to problems like these. It can bleed into the gel that fills the eye, pull the retina loose, and grow new vessels that block fluid from draining out of the eye4. There is treatment for each one, and it works best when it starts early. Most people with diabetic retinopathy never have a day like this. Knowing the signs just means you can act fast if you do. Nothing on this page asks you to start or stop a medicine on your own.
The honest answer is a qualified maybe, and the qualification matters. Large real-world studies of people taking SGLT2 inhibitors (medicines that make the kidneys pass extra sugar into the urine) have found less sight-threatening retinopathy than in people taking other diabetes pills5. But randomized trials, where people are assigned their treatment by chance, have not shown a clear effect on retinopathy either way6. So the signal is encouraging and the proof is not there yet.
This page can tell you what the evidence looks like today, what these pills are labeled to do, and what to ask at your next visit. It cannot tell you whether an SGLT2 inhibitor is right for your body. That decision belongs to you and the clinician who prescribes your diabetes medicines. If you already have diabetic retinopathy, your retina specialist should know every diabetes medicine you take.
What Jardiance and Farxiga Actually Are
Jardiance and Farxiga belong to a family of pills called SGLT2 inhibitors. The full name is sodium-glucose cotransporter 2 inhibitor, and the mechanism is simpler than the name. Your kidneys filter sugar out of your blood and normally pull most of it back in. These pills block that pull-back step, so extra sugar leaves in urine. Blood sugar falls, and so does the workload on the heart and kidneys. Jardiance is the brand name for empagliflozin, and Farxiga for dapagliflozin.
Neither pill is approved to treat an eye condition. The FDA has approved empagliflozin to lower the risk of cardiovascular death and heart failure hospitalization in adults with heart failure, to slow kidney decline in adults with chronic kidney disease at risk of getting worse, to lower the risk of cardiovascular death in adults with type 2 diabetes and established heart disease, and to improve blood sugar control in type 2 diabetes, with no eye indication on the label7. Dapagliflozin carries a similar set of labeled uses, again with no eye indication8. Any effect on your retina would be a side benefit of better metabolic control, not an approved use.
High blood sugar over years damages the tiny blood vessels that feed the retina. Weakened vessels leak and close off, and the retina responds by growing fragile new vessels that bleed easily. In type 2 diabetes, tighter blood glucose control lowered the rate of small-vessel complications, including the need for retinal laser treatment, compared with looser control9. That is the established link, and the most likely path by which any diabetes pill would help your eyes. Guidelines advise working on blood glucose, blood pressure, and blood lipids together to lower the chance that retinopathy develops or worsens10.
What the Research Says About SGLT2 Pills and Diabetic Retinopathy
Real-world studies follow people prescribed these pills in ordinary care. In a nationwide Taiwanese study that matched 403,622 adults with type 2 diabetes across three drug comparisons, sight-threatening retinopathy appeared in about 3.5 of every 1,000 SGLT2 inhibitor users each year, against about 6.1 of every 1,000 each year among matched users of a DPP-4 inhibitor, another common diabetes pill5. That gap is about 2.6 people in every 1,000 per year. Pooling 16 such studies covering more than 400,000 people, one review reported less retinopathy progression among SGLT2 inhibitor users, while noting the individual studies disagreed a great deal11.
Randomized trials are the stricter test, because chance decides who gets which treatment, which removes most hidden differences between groups. A network analysis of 30 randomized trials in more than 70,000 adults with type 2 diabetes found no SGLT2 inhibitor that clearly raised or lowered retinopathy risk against placebo6. Eye outcomes were not what those trials were built to measure, so they were recorded as side observations rather than tracked with retinal photographs. A neutral result from trials designed for other questions is weak evidence of no effect, not evidence against one.
The gap has plain explanations. People prescribed SGLT2 inhibitors in real life tend to have better access to care and closer follow-up than people on older pills, and that alone can make their eyes look better on paper. Insurance records also miss milder retinopathy. On the trial side, follow-up was often short. One large claims study found no link with new retinopathy over a mean of about 8 months, but did report less progression among people who already had it12.
Here is the honest scorecard. Nothing here rises to a treatment recommendation for your eyes, and no eye society currently advises choosing a diabetes pill on retinal grounds. The table below sorts the evidence by how much weight it can carry.
| Kind of evidence | What it suggests | How much weight |
|---|---|---|
| Large observational cohorts | Less retinopathy progression | Suggestive, not conclusive |
| Pooled cohort reviews | Same direction, wide disagreement | Moderate, heterogeneous |
| Randomized trials | No clear effect either way | Limited, eyes not the endpoint |
How These Pills Are Taken and What That Means for Your Eyes
These are once-a-day tablets, not injections and not eye drops. Empagliflozin is taken by mouth once each day in the morning, with or without food13. Your prescriber sets your strength, so follow your own bottle rather than any general description. Because these pills work through the kidneys, your kidney function is checked before you start and periodically afterwards. Drinking enough water matters more here than on most diabetes medicines, since these pills pull fluid out with the sugar.
Certain situations raise the risk of a serious reaction called ketoacidosis, in which acids build up in the blood. Ketoacidosis on these pills can happen even when your blood sugar readings look normal, which is why it is easy to miss1415. Vomiting, a bad infection, a very low-carbohydrate diet, heavy alcohol use, and the days around surgery all raise it. Ask your prescriber, in advance, for a written sick-day plan and for instructions about pausing the pill before any procedure, including eye surgery.
If you already take one of these pills, the retina evidence is not a reason to stop. If you do not, the retina evidence is not by itself a reason to start. Stopping a heart or kidney medicine on your own can undo a benefit far better established than the eye signal. Bring the question to your prescriber instead, and ask how your eyes fit the plan you already have.
Side Effects: What Is Common and What Needs Urgent Care
The everyday side effects come straight from the mechanism. Genital yeast infection is a labeled risk, and so are fluid loss and the lightheadedness that can come with a lower blood volume14. More urination is expected rather than a malfunction. Many people find these effects settle with good hygiene and steady fluids. Tell your prescriber about symptoms rather than quietly stopping the pill, since most have straightforward fixes and stopping costs you the heart and kidney benefit.
A few reactions are uncommon but serious enough to act on the same day.
- Nausea, vomiting, belly pain, deep or fast breathing, or unusual sleepiness, which can signal ketoacidosis
- Pain, tenderness, redness, or swelling between the genitals and the anus, especially with fever
- Burning with urination plus fever, back pain, or shaking chills
The labels list ketoacidosis, a rare deep tissue infection of the genital area, and serious urinary tract infection among the warnings for both medicines1415. These are rare. Seek care right away if they appear, because they respond to prompt treatment and get dangerous mainly when ignored.
The labeled risks of these pills are not eye risks. Neither label lists an eye problem among its warnings and precautions1415. Some people do notice temporary blurring after any change in diabetes treatment. Blurring that persists, worsens, or arrives with floaters or a shadow is a different matter, and it is worth having looked at rather than assuming it is the medicine settling in.
Who Should Not Take an SGLT2 Inhibitor
These medicines are not for everyone with diabetes. Empagliflozin is not recommended for blood sugar control in people with type 1 diabetes, because it may raise the risk of ketoacidosis in that group16, and dapagliflozin likewise is not indicated for blood sugar control in type 1 diabetes15. Anyone with a history of serious allergic reaction to the medicine should not take it. Your prescriber weighs kidney function, pregnancy plans, and your other conditions first.
Some people can take these pills but need closer watching. That group includes people who get dehydrated easily, people on water pills, older adults with low blood pressure, people with repeated genital or urinary infections, and anyone eating very few carbohydrates. Pregnancy and breastfeeding call for a different plan. If you have advanced retinopathy and your blood sugar is about to fall quickly, tell both your prescriber and your eye doctor.
Combinations matter as much as the pill itself. Taking one of these medicines alongside insulin or an insulin-releasing pill raises the chance of low blood sugar, so a lower amount of those may be needed15. Water pills add to fluid loss. Bring a full list of what you take, including anything off a pharmacy shelf, and ask what to do if you feel shaky, sweaty, or confused.
What to Expect for Your Vision Over the Next Few Years
Set your expectations at the population level, not the personal one. If the real-world findings hold up, the effect looks like a few fewer people per thousand each year developing sight-threatening disease5. That is meaningful across a population and invisible in any one person's life. No one can tell you how your own retinopathy will behave because of which diabetes pill you take. What these medicines do offer, on much better evidence, is heart and kidney protection.
There is a wrinkle worth knowing about any treatment that lowers blood sugar quickly. In one landmark trial, retinopathy worsened early, at the 6 or 12 month check, in about 13 of every 100 people on intensive glucose treatment compared with about 8 of every 100 on standard treatment, and roughly half of those cases had recovered by 18 months17. Early worsening clusters among people who already have retinopathy and whose hemoglobin A1c falls fastest, and eyes that dip early tend to end up the same or better in the long run when good control continues18. It has been studied mainly with treatments that drop blood sugar fast, such as intensive insulin and semaglutide, rather than with SGLT2 inhibitors18. Keep your eye appointments during any period of rapid change.
The things with the strongest evidence behind them are not glamorous. Guidelines put the emphasis on keeping your eye exams and on working with your clinicians toward better blood glucose, blood pressure, and blood lipid control10. All of that rests on firmer evidence than the retina question this page is about. When retinopathy does reach a sight-threatening stage, treatments exist, including injections into the eye, laser, and surgery4. Early detection keeps those options on the table.
When to Call and How Often to Get Your Eyes Checked
Once a year is the floor, not the ceiling. People with diabetes should have a comprehensive dilated eye exam at least once a year, and those who already have retinopathy may need checks every few months4. Guidelines advise that exam at the time of a type 2 diabetes diagnosis and at least yearly afterwards10. It matters because early diabetic retinopathy usually causes no symptoms4, so your own vision is not a reliable alarm. About 26 of every 100 people with diabetes in the United States had diabetic retinopathy in a 2021 estimate19, which makes the exam routine rather than alarming.
Between the emergencies at the top of this page and your yearly exam, there is a middle zone. Call for an appointment within a week or so if you notice gradual blurring that does not clear, new trouble reading, washed-out colors, a small blank spot in your central vision, or vision that shifts with your blood sugar. None of these means disaster. They mean the retina deserves a look sooner than your next slot.
Match the symptom to the clinician. Vision changes go to your eye doctor, an optometrist or ophthalmologist, and sudden ones go there the same day. Questions about taking, keeping, or pausing a diabetes pill go to whoever prescribes it. Questions in between, such as whether a fast drop in your A1c should change your eye follow-up, deserve both. Ask each to send a note to the other.
Common Questions About SGLT2 Pills and Diabetic Retinopathy
No. Nothing in the evidence supports undoing existing damage with a diabetes pill. The most the current research suggests is a possible slowing of progression in people who already have early retinopathy, and even that comes from observational studies rather than randomized trials12. Damage already present is addressed with eye-specific treatments once it threatens sight4. Think of blood sugar control as protecting what you still have.
There is no reliable evidence that one is better than the other for the retina. Most retinopathy research groups SGLT2 inhibitors as a single class, and the trial analysis that ranked individual agents found the differences between them were not statistically meaningful6. Choose between them on the grounds your prescriber uses anyway: your heart and kidney situation, other conditions, side effect history, and cost. Any eye difference is too uncertain to steer that decision.
Not for your eyes alone. The eye evidence is not strong enough to justify a switch on its own, and changing diabetes medicines has real consequences for blood sugar, kidney function, and cost. These medicines do have well-established heart and kidney benefits7, so it is a fair question to raise for those reasons. Bring it as an open question rather than a request, and let your prescriber weigh it against your full picture.
It is worth a conversation, not worry. A rapid fall in blood sugar has been linked with temporary worsening of retinopathy, mostly in people who already have it and whose levels drop the furthest and fastest18. The effect is usually short-lived, and long-term outcomes still favor good control17. Tell your eye doctor about the change and ask whether your next exam should move up. Do not slow down your diabetes treatment on your own to protect your eyes.
Usually yes, and this is a question for the clinician who prescribes the pill rather than one to settle alone. The thing worth flagging to both teams is any planned procedure, since the days around surgery are a recognized time of higher ketoacidosis risk on these medicines14. Your retina specialist should have your full medicine list, and your prescriber should know about upcoming eye procedures. Ask each directly rather than assuming the information traveled.
More Questions People Bring to Their Retina Specialist
Nobody can give you a reliable number. The observational studies that suggest benefit followed people for months to years, and one large claims study saw a signal for slowed progression over a mean follow-up of about 8 months12. Because the underlying damage builds over years, any real protective effect would accumulate slowly. It is a long-term side consideration, not something to check for at your next visit.
Yes, and it is the main reason to stay cautious. Insurance records show which codes were billed, not what a retina photograph showed, so milder retinopathy is often missed and severity is estimated rather than measured. People prescribed newer medicines also differ from those on older ones in ways records cannot fully adjust for. Researchers use matching to narrow that gap5, but it shrinks the problem rather than removing it.
No trial built specifically to test whether these pills protect the retina has reported yet. Dedicated eye-outcome trials are what the field says it needs, and the authors of the randomized-trial analysis called for exactly that6. Until one reports, the question stays open. If you want to follow it, ask your retina specialist whether a study near you is enrolling people with diabetic retinopathy. A trial is an option to explore, never an obligation.
Because the strongest reasons to use them have nothing to do with your eyes. The labeled benefits for heart failure, kidney disease, and blood sugar rest on large randomized trials7. Your prescriber is likely enthusiastic about that evidence, and the retina findings are a welcome extra rather than the basis for the choice. Ask directly which benefit is driving the recommendation for you.
- Which benefit is this pill mainly for in my case: my heart, my kidneys, or my blood sugar?
- What stage is my diabetic retinopathy, and how fast has it changed?
- How quickly do you expect my A1c to fall, and should my eye exam move up?
- What is my written sick-day plan, and when should I pause this pill?
- What symptoms should make me call you the same day?
- Can my eye doctor and my prescriber send each other notes?
- American Academy of Ophthalmology, EyeSmart (2024). Reasons to See an Ophthalmologist.
- American Academy of Ophthalmology, EyeSmart (2024). Detached Retina: Torn Retina Symptoms.
- American Academy of Ophthalmology, EyeSmart (2024). What Is Glaucoma? Symptoms, Causes, Diagnosis, Treatment.
- National Eye Institute (NEI), National Institutes of Health (2024). Diabetic Retinopathy.
- JAMA Network Open (Yen FS et al.), nationwide Taiwanese cohort (2023). Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
- International Journal of Clinical Pharmacy (Ortiz-Seller A et al.) (2025). Sodium-glucose cotransporter-2 inhibitors and risk of diabetic retinopathy in type 2 diabetes: a network meta-analysis of randomised clinical trials.
- DailyMed, US National Library of Medicine (FDA label) (2026). JARDIANCE (empagliflozin) tablets, US prescribing information: Indications and Usage.
- DailyMed, US National Library of Medicine (FDA label) (2025). FARXIGA (dapagliflozin) tablets, US prescribing information: Indications and Usage.
- The Lancet, 352(9131):837-853 (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
- American Diabetes Association, Diabetes Care volume 49, page S261 (2026). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes 2026.
- International Ophthalmology, 45(1):406 (2025). SGLT2 inhibitors for delaying diabetic retinopathy: a systematic review and meta-analysis.
- JAMA Ophthalmology (Paik JM et al.), US claims-based new-user cohort (2025). Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.
- DailyMed, US National Library of Medicine (FDA label) (2026). JARDIANCE (empagliflozin) tablets, US prescribing information: Dosage and Administration.
- DailyMed, US National Library of Medicine (FDA label) (2026). JARDIANCE (empagliflozin) tablets, US prescribing information: Ketoacidosis, Volume Depletion, Urosepsis, Fournier's Gangrene, Genital Mycotic Infections, Hypoglycemia.
- DailyMed, US National Library of Medicine (FDA label) (2025). FARXIGA (dapagliflozin) tablets, US prescribing information: Warnings and Precautions.
- DailyMed, US National Library of Medicine (FDA label) (2026). JARDIANCE (empagliflozin) tablets, US prescribing information: Warnings and Precautions.
- Archives of Ophthalmology, 116(7):874-886 (PMID 9682700) (1998). Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial.
- Endocrinology and Metabolism, 40(5):702-705 (2025). Rapid Glycemic Correction and the Paradox of Retinopathy Progression.
- American Academy of Ophthalmology, EyeNet Magazine (2023). 2021 Prevalence of Diabetic Retinopathy in the United States (reporting Lundeen et al., JAMA Ophthalmology).